HRP20220619T1 - Postupci za liječenje ar+ raka dojke - Google Patents
Postupci za liječenje ar+ raka dojke Download PDFInfo
- Publication number
- HRP20220619T1 HRP20220619T1 HRP20220619TT HRP20220619T HRP20220619T1 HR P20220619 T1 HRP20220619 T1 HR P20220619T1 HR P20220619T T HRP20220619T T HR P20220619TT HR P20220619 T HRP20220619 T HR P20220619T HR P20220619 T1 HRP20220619 T1 HR P20220619T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- esr1
- use according
- inhibitors
- optionally
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims 2
- 208000026310 Breast neoplasm Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 15
- 230000035772 mutation Effects 0.000 claims 8
- 102100038595 Estrogen receptor Human genes 0.000 claims 7
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims 7
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 5
- -1 SERDs Substances 0.000 claims 5
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims 3
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 3
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 3
- 239000012828 PI3K inhibitor Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 3
- 229950009216 sapanisertib Drugs 0.000 claims 3
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 2
- 239000012661 PARP inhibitor Substances 0.000 claims 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- 229950006418 dactolisib Drugs 0.000 claims 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical group O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960004390 palbociclib Drugs 0.000 claims 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 2
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 claims 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims 1
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 claims 1
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 claims 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- RAYNZUHYMMLQQA-ZEQRLZLVSA-N 2,3,5-trihydroxy-7-methyl-n-[(2r)-2-phenylpropyl]-6-[1,6,7-trihydroxy-3-methyl-5-[[(2r)-2-phenylpropyl]carbamoyl]naphthalen-2-yl]naphthalene-1-carboxamide Chemical compound C1([C@@H](C)CNC(=O)C=2C3=CC(C)=C(C(=C3C=C(O)C=2O)O)C=2C(O)=C3C=C(O)C(O)=C(C3=CC=2C)C(=O)NC[C@H](C)C=2C=CC=CC=2)=CC=CC=C1 RAYNZUHYMMLQQA-ZEQRLZLVSA-N 0.000 claims 1
- WUGANDSUVKXMEC-UHFFFAOYSA-N 2-[4-[(4-bromophenyl)sulfonylamino]-1-hydroxynaphthalen-2-yl]sulfanylacetic acid Chemical compound C=12C=CC=CC2=C(O)C(SCC(=O)O)=CC=1NS(=O)(=O)C1=CC=C(Br)C=C1 WUGANDSUVKXMEC-UHFFFAOYSA-N 0.000 claims 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 claims 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 1
- XMBUPPIEVAFYHO-KPZWWZAWSA-N 2-chloro-4-[[(1r,2s)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile Chemical group N([C@H]([C@@H](O)C)C=1OC(=NN=1)C=1C=CC(=CC=1)C#N)C1=CC=C(C#N)C(Cl)=C1C XMBUPPIEVAFYHO-KPZWWZAWSA-N 0.000 claims 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 claims 1
- UFKLYTOEMRFKAD-UHFFFAOYSA-N 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound C1CC(OC)CCC1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-UHFFFAOYSA-N 0.000 claims 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims 1
- GMYLVKUGJMYTFB-UHFFFAOYSA-N 5-ethyl-3-[2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=N1)C)=CC=C1C1=NN=CN1 GMYLVKUGJMYTFB-UHFFFAOYSA-N 0.000 claims 1
- VBTUJTGLLREMNW-UHFFFAOYSA-N 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione Chemical compound FC1=CC=C(CN2C(NC(=O)C3=C(F)C=CC=C32)=O)C=C1C(=O)N(CC1)CCN1C1=NC=CC=N1 VBTUJTGLLREMNW-UHFFFAOYSA-N 0.000 claims 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 1
- ACCFLVVUVBJNGT-AWEZNQCLSA-N 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C[C@H](C)OC)C(C2=C3)=C1C=NC2=CC=C3C1=CN=CC(C(C)(C)O)=C1 ACCFLVVUVBJNGT-AWEZNQCLSA-N 0.000 claims 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- BBUVDDPUURMFOX-SAABIXHNSA-N AMG-925 Chemical compound C1C[C@@H](C)CC[C@@H]1N1C2=NC(NC=3N=C4CCN(CC4=CC=3)C(=O)CO)=NC=C2C2=CC=NC=C21 BBUVDDPUURMFOX-SAABIXHNSA-N 0.000 claims 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 claims 1
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 claims 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 1
- UFKLYTOEMRFKAD-SHTZXODSSA-N C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-SHTZXODSSA-N 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 229940124640 MK-2206 Drugs 0.000 claims 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 claims 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 claims 1
- 229950001573 abemaciclib Drugs 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 229950010482 alpelisib Drugs 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 229950003628 buparlisib Drugs 0.000 claims 1
- JROFGZPOBKIAEW-HAQNSBGRSA-N chembl3120215 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1[C@H]1CC[C@H](C(O)=O)CC1 JROFGZPOBKIAEW-HAQNSBGRSA-N 0.000 claims 1
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical group CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 claims 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 1
- 229950004847 navitoclax Drugs 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- 229950011068 niraparib Drugs 0.000 claims 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 229950003687 ribociclib Drugs 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 1
- 229950000055 seliciclib Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229950004550 talazoparib Drugs 0.000 claims 1
- 229950001269 taselisib Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950007127 trilaciclib Drugs 0.000 claims 1
- 229950011257 veliparib Drugs 0.000 claims 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Spoj, naznačen time, da je to RAD140 (Spoj III):
[image]
ili njegova farmaceutski prihvatljiva sol, ili njegov farmaceutski prihvatljiv solvat, za uporabu u postupku liječenja AR+/ER+ raka dojke.
2. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, da se spoj primjenjuje oralnim putem.
3. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time, da:
(i) pojedinac se liječi adjuvantnom terapijom;
(ii) kod pojedinca je došlo do progresije bolesti nakon liječenja s jednim ili više endokrinoloških sredstava; opcionalno gdje se jedno ili više endokrinoloških sredstava bira iz skupine koju čine SERM-ovi, SERD-ovi, progestini, inhibitori aromataze, i njihove kombinacije; ili
(iii) kod navedenog pojedinca je došlo do progresije bolesti nakon liječenja s jednim ili više sredstava koji se biraju iz skupine koju čine CDK4/6 inhibitori, mTOR inhibitori, BCL-2 inhibitori, PI3K inhibitori, i njihove kombinacije.
4. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da se spoj dozira između 10 i 500 mg, 10 mg i 250 mg, ili 25 mg i 250 mg na dan; opcionalno time, da je doza jednom na dan.
5. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da pojedinac eksprimira ESR1 koji sadrži jednu ili više mutacija.
6. Spoj za uporabu prema patentnom zahtjevu 5, naznačen time, da:
(i) navedena mutacija utječe na afinitet za vezanje liganda u usporedbi s nemutiranim ESR1; opcionalno gdje navedena mutacija rezultira u smanjenju afiniteta estradiola za mutirani ESR1 u usporedbi s nemutiranim ESR1; i/ili
(ii) navedena mutacija signalizira kroz ESR1 put ovisno o ligandu ili neovisno o ligandu; i/ili
(iii) navedena mutacija ima kao rezultat fuzijski protein koji sadrži najmanje 10 neprekidno povezanih aminokiselina iz slijeda od nemutiranog ESR1 i najmanje 10 neprekidno povezanih aminokiselina iz nekog drugog ljudskog proteina; i/ili
(iv) navedena mutacija dovodi do toga da u ESR1 nedostaje 10 ili više uzastopnih aminokiselina iz aminokiselinskog slijeda njegove normalne (nemutirane) domene koja veže ligand; i/ili
(v) navedena mutacija sadrži jednu ili više mutacija odabranih iz skupine koju čine ESR1-AKAP12, ESR1-CCDC170, ESR1-YAP1, ESR1-POLH, ESR1-PCDH11X, i njihove kombinacije.
7. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da liječenje nadalje obuhvaća primjenu CDK4/6 inhibitora; opcionalno gdje navedeni CDK4/6 inhibitor ima IC50 od < 100 nM protiv CDK4 i CDK6.
8. Spoj za uporabu prema patentnom zahtjevu 7, naznačen time, da se navedeni CDK4/6 inhibitor bira iz skupine koju čine palbociklib, ribociklib, trilaciklib, abemaciklib i AMG925.
9. Spoj za uporabu prema patentnom zahtjevu 8, naznačen time, da navedeni CDK4/6 inhibitor jest palbociklib.
10. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da navedeno liječenje nadalje obuhvaća primjenu:
(i) mTOR inhibitora; opcionalno gdje se navedeni mTOR inhibitor bira iz skupine koju čine sirolimus, temsirolimus, everolimus, ridafarolimus, i MLN0128; ili
(ii) PI3K inhibitora; opcionalno gdje navedeni PI3K inhibitor je BEZ235, GDC-0980, BKM120, GDC-0941, BYL719, GDC-0032, MK2206, GDC-0068, GSK2110183, GSK2141795, AZD5363, AZD2014, MLN0128 ili CC-223; ili
(iii) PARP inhibitora; opcionalno gdje navedeni PARP inhibitor je talazoparib, veliparib, niraparib, beigen290, E7449, KX01, ABT767, CK102, JPI289, KX02, IMP4297, SC10914, NT125, PJ34, VPI289, ili ANG-3186; ili
(iv) MCL-1 inhibitora; opcionalno gdje navedeni MCL-1 inhibitor je 7-(5-((4-(4-(N,N-dimetilsulfamoil)pioerazin-1-il)fenoksi)metil)-1,3-dimetil-1H-pirazol-4-il)-1-(2-morfolinoetil)-3-(3-(naftalen-1-iloksi)propil)-1H-indol-2-karboksilna kiselina, S63845, omakataksin, seliciklib, UMI-77, AT101, sabutoklaks, ili TW-37; ili
(v) BCL-2 inhibitora; opcionalno gdje navedeni BCL-2 inhibitor je venetoklaks, navitoklaks, ABT737, G3139, ili S55746.
11. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da navedeni pojedinac jest žena; opcionalno gdje navedena žena je žena u predmenopauzi ili je žena u postmenopauzi.
12. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da je rak dojke lokaliziran, odmakao ili metastatski.
13. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeno liječenje nadalje obuhvaća primjenu terapijskog sredstva odabranog iz skupine koju čine rapamicin, everolimus, ridaforolimus, temsirolimus, MLN0128, CC115, CC223, OSI-027, AZD8055, AZD2014, GDC-0980, SAR245409, LY3023414, NVP-BEZ235, NVP-BGT226, SF1126, i PKI-587.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662353350P | 2016-06-22 | 2016-06-22 | |
US201662377497P | 2016-08-19 | 2016-08-19 | |
US201762461546P | 2017-02-21 | 2017-02-21 | |
EP17816081.8A EP3474841B1 (en) | 2016-06-22 | 2017-06-20 | Ar+ breast cancer treatment methods |
PCT/US2017/038390 WO2017223115A1 (en) | 2016-06-22 | 2017-06-20 | Ar+ breast cancer treatment methods |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220619T1 true HRP20220619T1 (hr) | 2023-02-03 |
Family
ID=60675862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220619TT HRP20220619T1 (hr) | 2016-06-22 | 2017-06-20 | Postupci za liječenje ar+ raka dojke |
Country Status (20)
Country | Link |
---|---|
US (3) | US20170368036A1 (hr) |
EP (2) | EP4066827A1 (hr) |
JP (2) | JP7221699B2 (hr) |
KR (3) | KR20220035276A (hr) |
AU (2) | AU2017281038B2 (hr) |
CA (1) | CA3027563A1 (hr) |
DK (1) | DK3474841T3 (hr) |
ES (1) | ES2913470T3 (hr) |
HR (1) | HRP20220619T1 (hr) |
IL (2) | IL292659A (hr) |
LT (1) | LT3474841T (hr) |
MX (2) | MX2018015724A (hr) |
NZ (1) | NZ749192A (hr) |
PL (1) | PL3474841T3 (hr) |
PT (1) | PT3474841T (hr) |
RS (1) | RS63311B1 (hr) |
RU (2) | RU2769527C2 (hr) |
SG (1) | SG11201811225RA (hr) |
SI (1) | SI3474841T1 (hr) |
WO (1) | WO2017223115A1 (hr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
US20190240198A1 (en) * | 2018-02-05 | 2019-08-08 | Dean G. Tang | Formulations and methods for the treatment of cancers |
WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
JP2022521824A (ja) * | 2019-03-28 | 2022-04-12 | エッサ ファーマ,インコーポレイテッド | アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用 |
TW202114682A (zh) * | 2019-06-17 | 2021-04-16 | 法商施維雅藥廠 | Mcl-1抑制劑與乳癌標準療法之組合,其用途及醫藥組合物 |
JP2022543832A (ja) * | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
CA3174422A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
WO2022046594A1 (en) * | 2020-08-23 | 2022-03-03 | Texas Biomedical Research Institute | Treatment of infectious diseases using bcl-2 family protein inhibitors |
CN112321526B (zh) * | 2020-09-30 | 2023-09-22 | 西北师范大学 | 一种通过氧化还原-脱羧偶联反应合成杂芳甲胺类化合物的方法 |
JP2024503718A (ja) * | 2021-01-15 | 2024-01-26 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 乳がんを治療するための薬学的組成物及びその使用方法 |
US20220257552A1 (en) * | 2021-02-11 | 2022-08-18 | Veru, Inc. | Methods of prescreening and treating breast cancers with selective androgen receptor modulators |
WO2022199697A1 (en) * | 2021-03-26 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Oral capsule of parp inhibitor and preparation method thereof |
WO2023064782A2 (en) * | 2021-10-12 | 2023-04-20 | Baylor College Of Medicine | Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1547758A (en) | 1975-07-29 | 1979-06-27 | Shell Int Research | Herbicidal composition |
FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
DE19517430A1 (de) | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode |
UA51652C2 (uk) | 1995-06-08 | 2002-12-16 | Новартіс Аг | Спосіб гідрування імінів |
US5955574A (en) | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
US5969095A (en) | 1995-07-13 | 1999-10-19 | Biomeasure, Inc. | Analogs of parathyroid hormone |
US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
PT918774E (pt) | 1996-06-27 | 2002-05-31 | Ligand Pharm Inc | Compostos moduladores do receptor para androgenio e metodos |
US20090264534A1 (en) | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
FR2770842B1 (fr) | 1997-11-13 | 1999-12-17 | Oreal | Nouveaux composes derives de n-aryl 2-hydroxy alkylamides |
EP0922467A3 (en) | 1997-12-12 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Iontophoretic drug delivery |
JP4154017B2 (ja) | 1997-12-30 | 2008-09-24 | 久光製薬株式会社 | イオントフォレーシス装置および薬物ユニット |
US6159959A (en) | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
WO2001036039A2 (en) | 1999-11-17 | 2001-05-25 | Novartis Ag | Iontophoretic transdermal delivery of peptides |
US6544553B1 (en) | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
KR20020075388A (ko) | 1999-12-30 | 2002-10-04 | 시그널 파머슈티컬스 인크 | 에스트로겐 수용체의 조절 화합물 및 조절 방법 |
EP1299094A2 (en) | 2000-06-28 | 2003-04-09 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
EP1323431B1 (en) | 2000-08-03 | 2010-10-27 | Antares Pharma IPL AG | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
GEP20053586B (en) | 2000-08-24 | 2005-07-25 | Univ Tennessee Res Corp | Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same |
AU2006201538B2 (en) | 2000-08-24 | 2008-02-21 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
ATE428466T1 (de) | 2000-10-26 | 2009-05-15 | Alza Corp | Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen |
US6670386B2 (en) | 2001-07-31 | 2003-12-30 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
WO2003015761A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
DE60309667D1 (de) | 2002-02-15 | 2006-12-28 | Endorech Inc | Biphenylderivate und ihre verwendung als antiandrogene |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
AU2003237084C1 (en) | 2002-04-24 | 2009-03-26 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
EP1513547A4 (en) | 2002-05-23 | 2009-11-04 | Michael F Holick | USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY |
TW200307553A (en) | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
WO2003105772A2 (en) | 2002-06-13 | 2003-12-24 | Beth Israel Deaconess Medical Center, Inc. | Analogs of parathyroid hormone and pth-related protein as bone anabolic agents |
PT1557411E (pt) | 2002-07-12 | 2012-11-22 | Astellas Pharma Inc | Derivado de n-fenil-(2r,5s)dimetilpiperazina |
EP1553074B1 (en) | 2002-08-12 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
US7622592B2 (en) | 2002-11-01 | 2009-11-24 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
UA79504C2 (en) | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
JP4500689B2 (ja) | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的エストロゲン受容体モジュレーター |
EP1603858A2 (en) | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
US20060148893A1 (en) | 2003-06-10 | 2006-07-06 | Blanc Jean-Baptiste E | Chemical compounds |
WO2004110978A2 (en) | 2003-06-10 | 2004-12-23 | Smithkline Beecham Corporation | 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
CN1842320B (zh) | 2003-06-30 | 2013-06-19 | 阿尔扎公司 | 含有不挥发性平衡离子的用于经涂覆的微突出物的制剂 |
KR20060105735A (ko) | 2003-07-04 | 2006-10-11 | 니코메드 덴마크 에이피에스 | 경구용 부갑상선 호르몬 함유 약학 조성물 |
JP2007505120A (ja) | 2003-09-10 | 2007-03-08 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体調節因子としての17−複素環式−4−アザステロイド誘導体。 |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
AU2004287414B2 (en) | 2003-10-31 | 2010-11-25 | Alza Corporation | Self-actuating applicator for microprojection array |
US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
MXPA06005510A (es) | 2003-11-13 | 2006-12-14 | Johnson & Johnson | Composicion y aparato para distribucion transdermica. |
WO2005049574A1 (en) | 2003-11-20 | 2005-06-02 | Warner-Lambert Company Llc | Androgen receptor modulators |
IL159273A0 (en) | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
KR20130124576A (ko) | 2004-01-07 | 2013-11-14 | 앙도르쉐르슈 인코포레이티드 | 헬릭스 12 배향형 스테로이드계 약학 제품 |
ES2347973T3 (es) | 2004-01-22 | 2010-11-26 | Eli Lilly And Company | Moduladores selectivos de receptor de estrogeno para el tratamiento de sintomas vasomotores. |
IL160033A0 (en) | 2004-01-25 | 2004-06-20 | Transpharma Medical Ltd | Transdermal delivery system for polynucleotides |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7514470B2 (en) | 2004-03-03 | 2009-04-07 | Smithkline Beecham Corporation | Aniline derivatives as selective androgen receptor modulators |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
JP2007223901A (ja) | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
WO2005099707A1 (en) | 2004-04-08 | 2005-10-27 | Merck & Co., Inc. | 17 beta-acetamide-4-azasteroids as androgen receptor modulators |
TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
ATE525354T1 (de) | 2004-05-03 | 2011-10-15 | Janssen Pharmaceutica Nv | Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms) |
EP1753749B1 (en) | 2004-05-03 | 2014-07-30 | Janssen Pharmaceutica NV | Novel indole derivatives as selective androgen receptor modulators (sarms) |
MXPA06013115A (es) | 2004-05-11 | 2007-02-28 | Pfizer Prod Inc | Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica. |
EP1744683B1 (en) | 2004-05-13 | 2016-03-16 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
US7268232B2 (en) | 2004-05-17 | 2007-09-11 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
EP1758874A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Substituted thiazoleacetic acids as crth2 ligands |
JP4201818B2 (ja) | 2004-06-07 | 2008-12-24 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 選択的アンドロゲン受容体調節剤及びその使用方法 |
WO2006031715A2 (en) | 2004-09-10 | 2006-03-23 | Janssen Pharmaceutica N.V. | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms) |
AU2005287038B2 (en) | 2004-09-20 | 2012-02-02 | Janssen Pharmaceutica N.V. | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators |
CN101065363B (zh) | 2004-09-30 | 2012-05-02 | 詹森药业有限公司 | 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物 |
US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
JP2008515998A (ja) | 2004-10-13 | 2008-05-15 | スミスクライン ビーチャム コーポレーション | 化合物 |
AU2005310238A1 (en) | 2004-10-29 | 2006-06-08 | Merck Sharp & Dohme Corp. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
EP1817292B1 (en) | 2004-11-16 | 2015-04-08 | Janssen Pharmaceutica NV | Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms) |
CA2587780A1 (en) | 2004-11-18 | 2006-05-26 | Transpharma Medical Ltd. | Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents |
MX2007006180A (es) | 2004-11-23 | 2007-06-20 | Ptc Therapeutics Inc | Derivados de carbazol, carbolina, e indol utiles en la inhibicion de la produccion del factor de crecimiento endotelial vascular. |
AU2006205066B2 (en) | 2005-01-10 | 2012-05-17 | Acadia Pharmaceuticals Inc. | Aminophenyl derivatives as selective androgen receptor modulators |
JP2008536868A (ja) | 2005-04-15 | 2008-09-11 | スミスクライン・ビーチャム・コーポレイション | シアノアリールアミン |
SI1891038T1 (sl) | 2005-05-13 | 2009-04-30 | Lilly Co Eli | Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja |
JP2008546643A (ja) | 2005-06-06 | 2008-12-25 | スミスクライン ビーチャム コーポレーション | 4−置換アリールアミン誘導体および医薬組成物におけるその使用 |
US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
BRPI0611705A2 (pt) | 2005-06-24 | 2016-11-16 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto |
US20090227571A1 (en) | 2005-07-01 | 2009-09-10 | Ligand Pharmaceuticals Incorporated | Androgen Receptor Modulator Compounds and Methods |
EP1911743B8 (en) | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Grk阻害剤からなる強心薬 |
US7776859B2 (en) | 2005-10-14 | 2010-08-17 | Bristol-Myers Squibb Company | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function |
JP5449775B2 (ja) * | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
WO2007061964A1 (en) | 2005-11-18 | 2007-05-31 | 3M Innovative Properties Company | Methods for coating microneedles |
TW200730505A (en) | 2005-12-07 | 2007-08-16 | Merck & Co Inc | Polymorphs of an androgen receptor modulator |
US8632801B2 (en) | 2005-12-28 | 2014-01-21 | Alza Corporation | Stable therapeutic formulations |
WO2007087518A2 (en) | 2006-01-24 | 2007-08-02 | Janssen Pharmaceutica N.V. | 2-substituted benzimidazoles as selective androgen receptor modulators (sarms) |
AU2007220419B2 (en) | 2006-03-03 | 2012-03-15 | Orion Corporation | Selective androgen receptor modulators |
US20080039775A1 (en) | 2006-03-15 | 2008-02-14 | Alza Corporation | Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia |
US9119945B2 (en) | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
CA2656067C (en) | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
JP5215300B2 (ja) | 2006-07-12 | 2013-06-19 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 置換アシルアニリドおよびそれらの使用方法 |
MX2009000714A (es) | 2006-07-19 | 2009-07-27 | Osurf | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
AU2007287070C1 (en) | 2006-08-24 | 2013-02-14 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
EP2079466B1 (en) | 2006-09-29 | 2014-01-15 | GlaxoSmithKline LLC | Substituted indole compounds |
WO2008063279A2 (en) | 2006-10-03 | 2008-05-29 | Radius Health, Inc. | A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof |
US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
WO2008128100A1 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
US9114238B2 (en) | 2007-04-16 | 2015-08-25 | Corium International, Inc. | Solvent-cast microprotrusion arrays containing active ingredient |
GB0712099D0 (en) | 2007-06-22 | 2007-08-01 | Wivenhoe Technology Ltd | Transmission Of Audio Information |
US7834051B2 (en) | 2007-08-07 | 2010-11-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compounds |
US20090117158A1 (en) | 2007-10-23 | 2009-05-07 | Mahmoud Ameri | Transdermal sustained release drug delivery |
EP2277124B1 (en) | 2007-11-21 | 2016-11-09 | Medizinische Hochschule Hannover | Means for treating myosin-related diseases |
CA2709514A1 (en) | 2007-12-21 | 2009-07-02 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
WO2009082437A2 (en) | 2007-12-21 | 2009-07-02 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (sarms) and uses thereof |
WO2009105214A2 (en) | 2008-02-22 | 2009-08-27 | Radius Health, Inc. | Selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
WO2009137104A1 (en) | 2008-05-09 | 2009-11-12 | Radius Health, Inc. | Combination therapy for breastcancer comprising an antiestrogenic agent |
SI2297100T1 (sl) | 2008-05-16 | 2013-02-28 | Eli Lilly & Company | Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja |
WO2010022176A1 (en) | 2008-08-19 | 2010-02-25 | Ferring International Center S.A. | Methods of treatment for skeletal conditons |
WO2010074239A1 (ja) | 2008-12-26 | 2010-07-01 | 久光製薬株式会社 | マイクロニードルデバイス |
US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
US20100226966A1 (en) | 2009-03-03 | 2010-09-09 | Daddona Peter E | Method for transdermal controlled release drug delivery |
WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
PL2433940T3 (pl) | 2009-04-28 | 2015-03-31 | Chugai Pharmaceutical Co Ltd | Pochodna spiroimidazolonu |
US20110172609A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
IE20100174A1 (en) | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
JP5606778B2 (ja) | 2010-04-22 | 2014-10-15 | 大倉工業株式会社 | 手術用資材 |
CA2798145C (en) | 2010-05-04 | 2022-10-18 | Corium International, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
SI2568806T1 (sl) | 2010-05-12 | 2016-09-30 | Radius Health, Inc. | Režimi zdravljenja |
EP3225247B1 (en) | 2010-05-28 | 2020-09-02 | 3M Innovative Properties Company | Aqueous formulations for coating microneedle arrays |
US8642632B2 (en) * | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
JP5965909B2 (ja) | 2010-09-28 | 2016-08-10 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
WO2012075375A1 (en) | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
MX2013012349A (es) | 2011-04-22 | 2014-07-09 | Radius Health Inc | Metodo para suministro de farmaco para pth, pthrp y peptidos relacionados. |
CA2857502C (en) | 2011-11-30 | 2019-08-13 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
US9744149B2 (en) * | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) * | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) * | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
JP2016501221A (ja) * | 2012-11-28 | 2016-01-18 | ノバルティス アーゲー | 併用療法 |
CA2914742A1 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception |
US20160146819A1 (en) * | 2013-06-19 | 2016-05-26 | University Of Miami | Classification system, methods and kit for classifying, predicting and treating breast cancer |
-
2017
- 2017-06-20 EP EP22160700.5A patent/EP4066827A1/en active Pending
- 2017-06-20 AU AU2017281038A patent/AU2017281038B2/en active Active
- 2017-06-20 SI SI201731163T patent/SI3474841T1/sl unknown
- 2017-06-20 IL IL292659A patent/IL292659A/en unknown
- 2017-06-20 ES ES17816081T patent/ES2913470T3/es active Active
- 2017-06-20 KR KR1020227007658A patent/KR20220035276A/ko not_active IP Right Cessation
- 2017-06-20 US US15/628,559 patent/US20170368036A1/en not_active Abandoned
- 2017-06-20 PT PT178160818T patent/PT3474841T/pt unknown
- 2017-06-20 HR HRP20220619TT patent/HRP20220619T1/hr unknown
- 2017-06-20 DK DK17816081.8T patent/DK3474841T3/da active
- 2017-06-20 RU RU2018144427A patent/RU2769527C2/ru active
- 2017-06-20 EP EP17816081.8A patent/EP3474841B1/en active Active
- 2017-06-20 KR KR1020247016474A patent/KR20240090491A/ko active Search and Examination
- 2017-06-20 NZ NZ749192A patent/NZ749192A/en unknown
- 2017-06-20 CA CA3027563A patent/CA3027563A1/en active Pending
- 2017-06-20 KR KR1020197001876A patent/KR102397890B1/ko active IP Right Grant
- 2017-06-20 RU RU2022108295A patent/RU2022108295A/ru unknown
- 2017-06-20 JP JP2018566897A patent/JP7221699B2/ja active Active
- 2017-06-20 MX MX2018015724A patent/MX2018015724A/es unknown
- 2017-06-20 PL PL17816081T patent/PL3474841T3/pl unknown
- 2017-06-20 RS RS20220514A patent/RS63311B1/sr unknown
- 2017-06-20 WO PCT/US2017/038390 patent/WO2017223115A1/en unknown
- 2017-06-20 LT LTEPPCT/US2017/038390T patent/LT3474841T/lt unknown
- 2017-06-20 SG SG11201811225RA patent/SG11201811225RA/en unknown
-
2018
- 2018-12-12 IL IL263678A patent/IL263678B/en unknown
- 2018-12-14 MX MX2022001075A patent/MX2022001075A/es unknown
-
2019
- 2019-11-26 US US16/696,110 patent/US11771682B2/en active Active
-
2021
- 2021-12-08 AU AU2021282467A patent/AU2021282467B2/en active Active
-
2023
- 2023-02-02 JP JP2023014544A patent/JP2023055861A/ja active Pending
- 2023-09-29 US US18/478,029 patent/US20240207234A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
JP2019518765A5 (hr) | ||
Nunnery et al. | Targeting the PI3K/AKT/mTOR pathway in hormone-positive breast cancer | |
JP6742391B2 (ja) | 併用療法 | |
AU2019204938B2 (en) | Mdm2 inhibitors and combinations thereof | |
AU2017245301B2 (en) | Pharmaceutical combinations | |
JP2008501776A5 (hr) | ||
JP2021102640A (ja) | 癌を治療するための方法 | |
MX2017011635A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. | |
JP2018515613A (ja) | 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ | |
JP2007519705A (ja) | Cns障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル/ベンゾイソオキサゾールアザビシクロ誘導体の組合せ | |
JP2014505735A5 (hr) | ||
JP2007536311A5 (hr) | ||
JP2008533142A (ja) | α7ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物 | |
CA2611474A1 (en) | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor | |
JP2018508516A5 (hr) | ||
JP2012515787A5 (hr) | ||
JP2015516392A5 (hr) | ||
JP2019530706A5 (hr) | ||
JP2018512403A5 (hr) | ||
JP2006512324A5 (hr) | ||
JP2015517523A5 (hr) | ||
AU2018380174A1 (en) | Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
JP2008110970A5 (hr) | ||
WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer |